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Abstract
Sleep disturbance is a common comorbidity among patients with acromegaly [patients with growth hormone (GH)-secreting tumor]
due to somatotropic axis change and sleep apnea. However, no previous studies exist concerning sleep disturbance and delirium in
the early postoperative period in patients with acromegaly undergoing transsphenoidal tumor surgery. Herein, we aimed to compare
the incidence of postoperative sleep disturbance and delirium in the early postoperative period between patients with GH-secreting
and nonfunctioning pituitary tumors.
We retrospectively reviewed the medical records of 1286 patients (969 with nonfunctioning and 317 with GH-secreting tumors)
without history of psychological disease and sedative or antipsychotic use. We examined the use of antipsychotics/sedatives and
findings of psychology consultation within the first postoperative week. Only patients with sleep disturbance noted in medical records
were considered to have postoperative sleep disturbance. Patients with an Intensive Care Delirium Screening Checklist score of 4 or
more were considered to have postoperative delirium.
The incidence of postoperative sleep disturbance was higher in the GH-secreting group than in the nonfunctioning tumor group
(2/969 [0.2%] vs 6/317 [1.9%]; P= .004; odds ratio=9.328 [95% confidence interval, 1.873–46.452]). Univariable regression
analysis showed that only diagnosis (GH-secreting tumor or nonfunctioning tumor) was a risk factor for sleep disturbance, and not
sex, age, body mass index, American Society of Anesthesiologists physical status score, surgery duration, anesthesia duration,
anesthesia type, tumor size, cavernous sinus invasion, or bleeding. The incidence of postoperative deliriumwas comparable between
the 2 groups (6/969 [0.6%] vs 0/317 [0%]; P= .346).
Patients with acromegaly showed increased incidence of sleep disturbance than those with nonfunctioning tumors in the early
postoperative period after transsphenoidal tumor surgery. A prospective study evaluating sleep quality in patients with GH-secreting
tumors in the early postoperative period could be conducted based on our findings.
Abbreviations: ASA= American Society of Anesthesiologists, GH= growth hormone, IGF-1= insulin-like growth factor 1, REM=
rapid eye movement.
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General anesthesia and surgery can change the circadian rhythm
of melatonin secretion, and this change may cause sleep
disturbance and delirium in the postoperative period.[1] Especial-
ly within the first 3 postoperative days, sleep is highly fragmented
by easy arousal, but the sleep patterns gradually return to
normal.[2] Sleep in the first and second postoperative nights is
characterized by reduced total sleep time andmarkedly decreased
rapid eye movement (REM) and slow-wave sleep. However,
rebound REM sleep with increased density appears in the middle
of the first postoperative week[3,4] and could possibly be
associated with episodic hypoxemia and hemodynamic instabili-
ty.[5] Sleep disturbance could also be related to postoperative
delirium, a risk factor for prolonged hospital stay, cognitive
dysfunction, and poor activities of daily living after surgery.[6,7]
Previous studies have focused on quality of life impairments in
patients with pituitary adenoma, the most frequently encoun-
tered tumor in the pituitary gland.[8] Sleep disturbance is
prevalent among patients with pituitary adenoma and is an
important factor contributing to quality of life impairment.[9,10]
In particular, the relationship between sleep and the somatotropic
axis, including growth hormone (GH) secretion, has been
demonstrated.[11] Sleep disturbance is a common comorbidity
Kim et al. Medicine (2020) 99:45 Medicineamong patients with acromegaly (i.e., those with GH-secreting
tumor) due to hormonal imbalance and sleep apnea.[10] Even
among patients treated for acromegaly, sleep quality was reduced
comparedwith thatofnormal controls.[12] Irreversible change in the
upper airway could be responsible for the sleep disturbance in these
patients long after the condition has been cured.[10,12] A few studies
have reported the association between insulin-like growth factor 1
(IGF-1) and delirium, but the results were inconsistent.[13–16]
There are no previous studies on sleep disturbance and
delirium in the early postoperative period in patients with
acromegaly undergoing transsphenoidal tumor surgery. In this
retrospective study, we aimed to compare the incidence of
postoperative sleep disturbance and delirium in the first
postoperative week between patients with GH-secreting tumors
and patients with nonfunctioning tumors.
2. Methods
2.1. Study population and data collection
The study protocol was approved by the institutional review
board of the Yonsei University Health System, Seoul, South
Korea (#4-2018-0473). This study was conducted in accordance
with the ethical guidelines of the Helsinki Declaration. The
requirement of informed consent from the patients was waived
owing to the retrospective design of the study.
We queried our electronic medical records database for cases of
transsphenoidal pituitary surgery for GH-secreting or nonfunc-
tioning tumors under general anesthesia at a university hospital
between January 1, 2013, and February 28, 2018. The exclusion
criteria were age <18 years, history of radiotherapy or medical
treatment for pituitary tumor, preoperative diagnosis of
psychological disease, including sleep disturbance, preoperative
history of sedative or antipsychotic drug use, Cushing disease,
hypopituitarism, prolactinoma, craniopharyngioma, abnormal
thyroid function test, and insufficient medical data.
To determine the incidence of postoperative sleep disturbance
and delirium, we investigated the use of alprazolam, zolpidem,
and quetiapine, which are the drugs most commonly prescribed
as sedatives by neurosurgeons in our institution, and the need for
postoperative psychological consultation within the first postop-
erative week. Only those patients who clearly stated having sleep
disturbance such as reduced total sleep time or fragmented sleep
by easy arousal in progress notes, consultation notes, or nursing
records were considered to have postoperative sleep disturbance.
The patients were diagnosed with postoperative delirium by a
psychiatrist based on an Intensive Care Delirium Screening
Checklist (ICDSC) score of 4 or more. Two investigators
independently reviewed all medical records. We compared
postoperative sedative use and incidence of sleep disturbance
and delirium between patients with nonfunctioning tumors and
patients with GH-secreting tumors. We also compared serum
IGF-1 levels before and 3 days after the surgery in the GH-
secreting tumor group.
2.2. Statistical analysis
Descriptive data are presented as mean values±SD. For
intergroup comparisons, Chi-square test or Fisher exact test
was used for categorical variables and Student t-test orWilcoxon-
Mann–Whitney test was used for continuous variables. The effect
sizes were calculated according to Cohen W, and an effect size
less than 0.1 was considered to have sufficient power to detect2
differences between the 2 groups. Factors that affected
postoperative sleep disturbance were determined by univariable
and multivariable regression analysis. The regression analysis
included variables such as diagnosis (GH-secreting tumor or
nonfunctioning tumor), sex, age, body mass index (BMI),
American Society of Anesthesiologists (ASA) physical status,
duration of surgery, duration of anesthesia, type of anesthesia
(inhalation anesthesia vs total intravenous anesthesia), tumor
size, cavernous sinus invasion, and bleeding. All statistical
analyses were performed using SPSS Statistics 23 (IBM SPSS
Statistics for Windows, IBM Corp, Armonk, NY).3. Results
A total of 1286 patients, comprising 969 with nonfunctioning
tumors and 317 with GH-secreting tumors, were included in this
study (Fig. 1). The proportion of female patients was higher in the
nonfunctioning tumor group than that in the GH-secreting tumor
group. Although the nonfunctioning group included 284 patients
with ASA classification 1, all patients in the GH-secreting tumor
group had ASA classification of more than 2; therefore, there was
a difference in severity between the 2 groups. Especially, the
prevalence of hypertension and diabetes mellitus was higher in
the GH-secreting tumor group than that in the nonfunctioning
tumor group (Table 1).
3.1. Postoperative sleep disturbance and delirium
The incidence of postoperative sleep disturbance was higher in
the GH-secreting tumor group than that in the nonfunctioning
tumor group (2/969 [0.2%] vs 6/317 [1.9%]; P= .004; odds ratio
[OR]=9.328 [95% confidence interval (95% CI),1.873–
46.452]; effect size= .08; Table 2). Six of the eight patients with
sleep disturbance had used alprazolam, zolpidem, or quetiapine
at least once within the first postoperative week. The seventh
patient underwent psychiatric consultation for insomnia on the
first postoperative day, and the eighth patient complained of
difficulty falling asleep and easy arousal for 3 postoperative
nights (Table 3).
The incidence of postoperative delirium was comparable
between the 2 groups. Of the 969 patients in the nonfunctioning
tumor group, 6 were diagnosedwith postoperative delirium, while
none of the 317 patients in the GH-secreting tumor group were
diagnosed with postoperative delirium (6/969 [0.6%] vs 0/317
[0%]; P= .346; effect size= .026). Six patients with delirium in this
study presented with restlessness, agitation, hallucinations, or
delusions and had an ICDSC score of 4 or more.3.2. Postoperative sedative use
There was no significant difference in postoperative sedative use
between the nonfunctioning tumor and the GH-secreting tumor
groups (16/969 [1.7%] vs 9/317 [2.8%]; P= .238; OR=1.740
[95% CI, 0.761–3.978]); effect size= .031; Table 2).3.3. Serum IGF-1 level
In the GH-secreting tumor group, serum IGF-1 level measured 3
days after the surgery was significantly lower than that observed
preoperatively (336.40±133.96 vs 688.37 [223.58]; P< .001).
Reduction in IGF-1 was also observed in patients with
postoperative sleep disturbance (Table 3).
Figure 1. Flowchart of patient selection.
Kim et al. Medicine (2020) 99:45 www.md-journal.com3.4. Factors that affected postoperative sleep disturbance
Only the diagnosis (GH-secreting tumor or nonfunctioning
tumor) was found to be a risk factor for sleep disturbance in
univariable regression analysis, and not sex, age, BMI, ASA
physical status score, duration of surgery, duration of anesthesia,
type of anesthesia (inhalation anesthesia vs total intravenous
anesthesia), tumor size, cavernous sinus invasion, or bleeding.
Along with the diagnosis, variables which were different between
the 2 groups such as sex, age, BMI, ASA physical status score, and
duration of anesthesia were included in the multivariable
analysis. Multivariable regression model also showed that the
diagnosis (GH-secreting tumor or nonfunctioning tumor) was
the only factor that affected the incidence of sleep disturbance
(Table 4).Table 1





Age, yr 46.68±13.87 44.06±12.09 .001
Sex (male/female) 362/607 147/170 .004
Height, cm 164.45±8.34 168.27±10.11 <.001
Weight, kg 65.77±12.85 71.62±14.15 <.001
BMI 24.23±3.82 25.14±3.48 <.001
ASA (1/2/3/4) 284/558/123/4 0/261/55/1 <.001
Hypertension 198 (20.4%) 102 (32.2%) <.001
Diabetes mellitus 79 (8.2%) 74 (23.3%) <.001
Coronary artery disease 23 (2.4%) 4 (1.3%) .231
Duration of surgery, min 181.19±78.34 206.10±94.64 .002
Duration of anesthesia, min 273.80±89.41 291.95±100.76 .002
Tumor size (> 1cm) 871 (89.9%) 275 (86.8%) .120
Sinus invasion 372 (38.3%) 128 (40.4%) .528
Bleeding, mL 238.65±267.69 265.87±249.16 .110
Data are presented as mean± standard deviation for continuous variables and count (percentage) for
categorical variables.
ASA = American Society of Anesthesiologists, BMI = body mass index, GH = growth hormone.
3
4. Discussion
This is the first study to demonstrate that, in patients undergoing
transsphenoidal surgery, the incidence of sleep disturbance in the
early postoperative period is higher among patients with GH-
secreting pituitary tumors than among those with nonfunctioning
pituitary tumors. Univariable regression analysis showed that
only the diagnosis (GH-secreting tumor or nonfunctioning
tumor) was a significant risk factor for postoperative sleep
disturbance. Although only patients with nonfunctioning pitui-
tary tumors developed delirium, the difference between the
groups was not significant.
Acromegaly is a chronic disease that results from excess
secretion of GH, mostly caused by pituitary adenoma. GH is
produced in the somatotrophs of the anterior pituitary gland and
stimulates cell growth and proliferation in several major organs,
both directly and through the release of IGF-1. IGF-1 is produced
primarily in the liver by stimulation of GH and has growth-
promoting effects on numerous organs together with GH. It is
well known that GH secretion increases during sleep.[17] In
particular, the onset of nocturnal sleep is a potent stimulator of
GH secretion[18] and secretion increases during slow-wave sleep
(also known as deep sleep) compared with that during REM- and
stage 1 and stage 2 sleep.[19,20]Table 2
Differences in the incidence of postoperative sleep disturbance,
delirium, and antipsychotic use between the groups with






(N=317) P OR (95% CI)
Sleep disturbance 2 (0.2%) 6 (1.9%) .004 9.328 (1.87–46.45)
Delirium 6 (0.6%) 0 (0%) .346
Sedative use 16 (1.7%) 9 (2.8%) .238 1.740 (0.76–3.98)
Data are presented as count (percentage).
CI = confidence interval, GH = growth hormone, OR = odds ratio.
Table 3
Characteristics of patients with postoperative sleep disturbance.
Patient number Sex/age Preoperative IGF-1, mg/L
POD 3
IGF-1, mg/L Treatment
GH 1 F/56 494 242 Zolpidem 6.25mg (from operative day through POD 2), 10mg (from POD 3 to POD 4)
GH 2 F/56 321 108 Quetiapine 6.25mg (operative day)
GH 3 F/49 420 256 Consultation for sleep disturbance (POD 1), no medication
GH 4 F/62 501 100 Alprazolam 0.25mg (POD 6)
GH 5 F/42 590 327 Nursing records showed that the patient complained of sleep disturbance (from the
operative day through POD 2), no medication
GH 6 F/39 — — Zolpidem 12.5mg (POD 4), zolpidem 12.5mg + alprazolam 0.25mg (POD 5)
NF 1 F/31 — — Zolpidem 10mg (POD 6)
NF 2 M/56 — — Quetiapine 25mg (from operative day to POD 2)
F = female, GH = patients with growth hormone secreting tumors, IGF-1 = insulin like growth factor 1, M = male, NF = patients with nonfunctioning tumors, POD = postoperative day.
Kim et al. Medicine (2020) 99:45 MedicineIn the patients with GH-secreting tumors in this study, early
postoperative IGF-1 levels did not reduce to within the normal
range, but were significantly decreased compared with the
preoperative levels, which was consistent with the result of a
previous study.[21] GH secretion reaches its peak immediately after
sleep onset and is highly correlated to slow-wave sleep.[11,17–20,22]
Therefore, abrupt reduction in GH could possibly be responsible
for postoperative sleep disturbance. Normal IGF-1 values vary
with age and sex and do not fluctuate during the day; therefore,
IGF-1 levelmeasurement is used as a screening test for acromegaly.
The normalized IGF-1 level is also used as one of the criteria of
controlled GH status after the treatment of acromegaly.[23] In a
previous study, IGF-1 levels had returned to normalwithin the first
week after surgery for GH-secreting tumor removal.[21] GH
deficiency is associated with poor sleep quality and daytime
sleepiness.[24,25] In patients with GH deficiency after successful
treatment of acromegaly, quality of life, in terms of anxiety and
anger, remained lower than that in patients with sufficient GH
levels.[26] GH-releasing hormone administration was shown to
enhance the quality of sleep in patients with GH deficiency of
pituitary origin,[27] and GH replacement and correction of GH
levels resulted in a trendof increasing slow-wave sleepduration.[22]
In a previous study that examined the quality of life of patientswith
previous acromegaly long in remission (mean duration of
remission, 12 years), sleep quality was impaired compared with
that of a normal control population.[12] In the aforementioned
study, 48% of the patients underwent radiotherapy or somato-
statin-analogue therapy together with surgical treatment and 8%Table 4
Univariable and multivariable logistic regression models of factors a
Univariable
Variables OR 95% CI




Duration of surgery 1.000 0.99–1.01
Duration of anesthesia 1.000 0.99–1.01
Type of anesthesia 0.571 0.12–2.77
Bleeding 1.000 1.00–1.00
Tumor size (> 1cm) 0.421 0.09–2.05
Sinus invasion 0.625 0.12–3.24
BMI 0.856 0.68–1.07
ASA = American Society of Anesthesiologists physical status classification, BMI = body mass index, C
4
of patients did not undergo surgery. Our study differs from the
previous one in that we excluded the effects of other medical
treatments and only assessed the effects of general anesthesia and
transsphenoidal surgery on postoperative sleep disturbances.
A few studies have reported on the relationship between low
IGF-1 level and delirium,[13,14] but in other studies with patients
undergoing surgery, there was no relationship between preopera-
tive IGF-1 level and postoperative delirium.[15,16] Generally, IGF-1
decreases during surgery and anesthesia.[28]However, in rare cases
of IGF-1 increase during surgery, the increase was associated with
postoperative delirium.[16] Delirium is classified into 3 types:
hyperactive, hypoactive, and mixed type; hyperactive delirium,
characterized by restlessness and agitation, is known to concern
less than 2% of total delirium cases.[29] In this study, 6 of 969
patients with nonfunctioning tumors developed hyperactive
delirium, and given that the incidence of postoperative delirium
in patients undergoing neurosurgery is approximately 10%, the
incidence of delirium in these patients is consistent with the
previously reported incidence.[30] Although not statistically
significant, it is noteworthy that delirium occurred only in patients
with nonfunctioning pituitary tumors. In a previous study,
improvement in sleep quality through environmental noise and
light reduction interventions during the night was associated with
low incidence of delirium.[31] Changes in the somatotropic axis
of patients with acromegaly might affect the occurrence of
postoperative delirium. In a previous study on the personality of
patients with pituitary tumors, patients with acromegaly showed
less impulsivity than those with nonfunctioning tumors,[32] andssociated with postoperative sleep disturbance.
Multivariable
P OR 95% CI P
.006 17.731 2.05–153.25 .009
.153 4.305 0.49–37.84 .188
.231 1.024 0.96–1.09 .459
.351 0.809 0.03–21.78 .900
.948





.171 0.807 0.60–1.08 .147
I = confidence interval, GH = growth hormone, OR = odds ratio.
Kim et al. Medicine (2020) 99:45 www.md-journal.comthese characteristics could possibly be one of the reasons that
we observed no postoperative delirium among patients with
acromegaly in this study. Further studies on the relationship
between GH and postoperative delirium are required to determine
the incidence of postoperative delirium among patients with
acromegaly.
This study has some limitations. First, because this study was
based on electronicmedical records,we could not use standardized
polysomnographic recordings or questionnaires to diagnose sleep
disturbances. However, we consider that the use of antipsychotic/
sedative medication or the need for psychological consultation in
postoperative patients without prior history of sleep disturbances
signifies the onset of relatively severe sleep disturbance due to
surgery. Second, because we could not apply delirium screening
methods to all patients in the study population, a considerable
number of cases of deliriummight have gone unnoticed.However,
we believe that significant results regarding hyperactive delirium
could be obtained from the medical records.5. Conclusion
Patients with acromegaly showed increased incidence of sleep
disturbance than those with nonfunctioning tumors in the early
postoperative period after transsphenoidal tumor surgery. This is
the first study to evaluate the effect of surgery and general
anesthesia alone on sleep disturbance in patients with acromegaly
and could serve as a basis for a prospective study that will
evaluate sleep quality and delirium incidence in the early
postoperative period among patients with GH-secreting tumors.
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